A new blood test that could help predict coronary heart disease has been cleared by the U.S. Food and Drug Administration.
The PLAC Test monitors levels of Lp-PLA2, an enzyme in the blood that is produced inside built-up plaque by inflammatory cells in the arteries. Lp-PLA2 is a biological marker of inflammation in the arteries, which is associated with the buildup of plaque in the arteries.
Test results show that patients with Lp-PLA2 activity levels greater than 225 nanomoles per minute per milliliter (nmol/min/mL) are at greater risk of developing heart attacks or ischemic strokes associated with atherosclerosis.
The blood test could provide healthcare professionals with additional information about a patient’s health conditions along with regular cholesterol tests, which tell very little about the acute risk of heart attack or stroke.